71 results
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA … , investigation or proceeding; (E) has not received notice that the FDA or any Governmental Entity has taken, is taking or intends to take action to limit
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an insider trading investigation conducted either by the U.S. Securities and Exchange Commission (the “SEC”) or the U.S. Department of Justice, even … in a violation of law. Needless to say, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish one’s
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
applicable, any comparable filing(s) outside the U.S. for the investigation of any product in any other country or group of countries (such as a Clinical … of any of the following: (a) any pending or threatened litigation, governmental investigation, proceeding or action involving the Product; (b) any
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation … dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been
6-K
EX-3.1
MREO
Mereo Biopharma Group Plc
18 Dec 23
Current report (foreign)
4:10pm
of the provisions referred to in section 205(5) of the Companies Acts; and
(ii)
in defending an investigation against them by a regulatory authority
6-K
EX-3.1
890ku0 02
17 May 22
Current report (foreign)
8:26am
6-K
EX-99.1
jhlhgyc qnu
9 May 22
Current report (foreign)
8:06am
6-K
dh76fqx
9 May 22
Current report (foreign)
8:06am
6-K
EX-99.1
l1vkqep9z8i8g
14 Mar 22
Current report (foreign)
10:05am
6-K
EX-99.1
779ifyx
30 Nov 21
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of
7:51am
6-K
EX-99.1
4gu rje1icaknrqbr0st
26 Oct 21
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in About Mereo BioPharma
10:07am
6-K
EX-99.1
fobdmwm
1 Oct 21
Current report (foreign)
4:43pm